2.50
Hdl Handle:
http://hdl.handle.net/10541/109662
Title:
Ovarian cancer family and prophylactic choices.
Authors:
Evans, D Gareth R; Ribeiro, G; Warrell, D; Donnai, D
Abstract:
A subject from a family with ovarian cancer who has developed bilateral medullary carcinoma of the breast at the age of 40 is presented. The family is consistent with dominant inheritance of ovarian cancer and 12 female family members at 12.5%, 25%, and 50% risk, including our case, have undergone bilateral prophylactic oophorectomy and been given hormone replacement therapy. Despite the risk of further primary tumours of the breast our patient chose to have treatment with wide excision and radiotherapy. The implications for screening, prophylaxis, and hormone replacement therapy for this family are discussed.
Affiliation:
CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Christie Hospital, Manchester.
Citation:
Ovarian cancer family and prophylactic choices. 1992, 29 (6):416-8 J. Med. Genet.
Journal:
Journal of Medical Genetics
Issue Date:
Jun-1992
URI:
http://hdl.handle.net/10541/109662
DOI:
10.1136/jmg.29.6.416
PubMed ID:
1320125
Type:
Article
Language:
en
ISSN:
0022-2593
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorEvans, D Gareth Ren
dc.contributor.authorRibeiro, Gen
dc.contributor.authorWarrell, Den
dc.contributor.authorDonnai, Den
dc.date.accessioned2010-08-16T14:55:58Z-
dc.date.available2010-08-16T14:55:58Z-
dc.date.issued1992-06-
dc.identifier.citationOvarian cancer family and prophylactic choices. 1992, 29 (6):416-8 J. Med. Genet.en
dc.identifier.issn0022-2593-
dc.identifier.pmid1320125-
dc.identifier.doi10.1136/jmg.29.6.416-
dc.identifier.urihttp://hdl.handle.net/10541/109662-
dc.description.abstractA subject from a family with ovarian cancer who has developed bilateral medullary carcinoma of the breast at the age of 40 is presented. The family is consistent with dominant inheritance of ovarian cancer and 12 female family members at 12.5%, 25%, and 50% risk, including our case, have undergone bilateral prophylactic oophorectomy and been given hormone replacement therapy. Despite the risk of further primary tumours of the breast our patient chose to have treatment with wide excision and radiotherapy. The implications for screening, prophylaxis, and hormone replacement therapy for this family are discussed.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogenen
dc.subjectMultiple Primary Canceren
dc.subjectOvarian Canceren
dc.subject.meshAdult-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCarcinoma-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshEstrogens, Conjugated (USP)-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms, Multiple Primary-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshOvariectomy-
dc.subject.meshPedigree-
dc.subject.meshTamoxifen-
dc.titleOvarian cancer family and prophylactic choices.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Christie Hospital, Manchester.en
dc.identifier.journalJournal of Medical Geneticsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.